Compare Medtronic PLC (MDT) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Medtronic PLC trades at $88.94 (market cap $116.07B), while Vanguard Intermediate Term Corporate Bond ETF trades at $81.3. The key difference: Medtronic PLC pays a 3.18% dividend while Vanguard Intermediate Term Corporate Bond ETF pays none, and Medtronic PLC is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| MDT | VCIT | |
|---|---|---|
Market Cap | $116.07B | — |
Sector | Health | Fixed Income |
52-Week High | $105.35 | $84.82 |
52-Week Low | $73.75 | $81.07 |
Enterprise Value | $134.82B | — |
Dividend Yield | 3.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $89.41, up 2.58% on the day, reflecting positive momentum. The stock exhibits bullish technical signals with strong moving average support and a consensus analyst price target of $98.75. Fundamentally, the company reported revenue of $33.54B for 2025 with a net income margin of 13.2%, and has consistently beaten EPS estimates in recent quarters. Recent news highlights institutional acquisitions and positive developments in medical technology platforms.
The outlook for MDT is positive, driven by earnings beats, robust cash flow, and growth in cardiac and robotic surgery segments. Key opportunities include undervaluation relative to analyst targets and dividend stability. Risks involve rising debt levels and competitive pressures in the medtech sector. The stock presents a compelling case for growth-oriented income investors.
VCIT, the Vanguard Intermediate-Term Corporate Bond ETF, trades at $81.295 with a modest 0.28% daily gain. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. The fund maintains competitive advantages with its ultra-low 0.03% expense ratio and approximately 5% yield, holding over 2,000 investment-grade corporate bonds. Recent dividend distributions of $0.33-0.34 highlight its income-focused strategy.
The outlook for VCIT remains favorable for income investors seeking corporate bond exposure with low costs. Key opportunities include the fund's yield advantage over treasury alternatives and consistent monthly distributions. Risks involve interest rate sensitivity and corporate credit quality concerns during economic uncertainty. Wall Street sentiment is generally positive given the fund's cost efficiency and diversification benefits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
